Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase.
- Author:
Zi-liang WU
1
;
Fu-xiong CHEN
;
Tie-zhen YE
;
Yong-hong LAI
;
Yan-qin CUI
;
Ya-wei ZOU
;
Cheng-yu LU
;
Shu-ling LAN
;
Guo-yu ZHONG
;
Jing-ming GUAN
;
Feng-Gui WEI
;
Hui ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Antineoplastic Agents; administration & dosage; adverse effects; blood; Asparaginase; administration & dosage; adverse effects; blood; Child; Child, Preschool; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; drug therapy; Treatment Outcome
- From: Chinese Journal of Hematology 2006;27(1):14-16
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the safety and therapeutic effect of low dose (1000 U/m(2)) L-asparaginase (L-Asp) in the treatment of children with acute lymphoblastic leukemia (ALL).
METHODSSix patients were treated with low dose L-Asp after previously suffered severe side effects from standard dose L-Asp (5000 - 10,000 U/m(2)). Twenty-eight blood samples were obtained randomly from 5 of them. Plasma asparagine concentration was detected by reverse phase-high performance liquid chromatography (RP-HPLC).
RESULTSAll the patients treated with low dose L-Asp showed no any toxic symptoms. The plasma asparagine levels in the patients were all above 5 micromol/L except case 4 (4.91 micromol/L) before receiving L-Asp, and were all decreased below 0.5 micromol/L five days after receiving low dose L-Asp, except case 3 (3.70 micromol/L), the results being like that of receiving standard dose L-Asp.
CONCLUSIONLow dose L-Asp has definite efficacy for childhood ALL, while avoids serious side effects from standard dose L-Asp.
